The invention is related to the fully effective gastro-protected universal oral delivery device of gastro-protected nanoparticles for the transport of intact biologically active polypeptides into the circulatory system. This universal oral delivery device is made of gastro-protected nanoparticles that transport intact therapeutic polypeptides through the gastrointestinal system and it successfully performs the paracellular transepithelial passage of all therapeutic polypeptides from the intestinal lumen into the circulatory system, fully preserving the integrity and biological activity of those therapeutic polypeptides.

The invention is related to the fully effective gastro-protected universal oral delivery device of gastro-protected nanoparticles for the transport of intact biologically active polypeptides into the circulatory system. This universal oral delivery device is made of gastro-protected nanoparticles that transport intact therapeutic polypeptides through the gastrointestinal system and it successfully performs the paracellular transepithelial passage of all therapeutic polypeptides from the intestinal lumen into the circulatory system, fully preserving the integrity and biological activity of those therapeutic polypeptides.

The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.

The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.

The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.

This invention relates to methods of using salt inducible kinase inhibitors to enhance female fertility.

This invention relates to methods of using salt inducible kinase inhibitors to enhance female fertility.

Systems and methods for implementing machine-learning models for ovarian stimulation is described herein. In some variations, a computer-implemented method may include optimizing an ovarian stimulation process may include receiving patient-specific data associated with a patient, and predicting an egg outcome for the patient for each of a plurality of treatment options for an ovarian stimulation process based on at least one predictive model and the patient-specific data, where the at least one predictive model is trained using prior patient-specific data associated with a plurality of prior patients.

A method of administering elagolix to a patient in association with an artificial reproductive technology (ART) protocol involves orally administering 150 to 400 mg elagolix per day. In accordance with certain embodiments, the method further involves the co-administration of exogenous gonadotropins (rFSH or HMG) with a subsequent ovulatory trigger. In an embodiment, the patient is administered 150 to 200 mg Elagolix PO daily or twice per day. In an embodiment, the patient is administered 150 to 200 mg Elagolix PO per day at a dosing duration of a minimum of one day and a maximum of six days. In an embodiment, the ART protocol involves administering 150 to 200 mg Elagolix PO per day based upon a patient's transvaginal ultrasound and hormone levels.